Answers are grounded in this paper and cite their sources.
Human immunoglobulin A (IgA) exists as two subclasses, IgA1 and IgA2, which differ mainly in the hinge region: IgA1 has an extended, O-glycosylated hinge that confers conformational flexibility but is cleaved by IgA1-specific bacterial proteases, whereas the short hinge of IgA2 resists proteolysis. The subclasses also differ in their distribution between serum and mucosal secretions, in their preference for protein or polysaccharide antigens, and in the glycosylation of the Fc region, which modulates binding to the Fcα receptor (FcαRI/CD89) and, consequently, the balance between anti-inflammatory and pro-inflammatory effects. Drawing on a narrative review of the literature indexed in PubMed/MEDLINE, Scopus, and Web of Science, we summarize the structural and functional features of IgA1 and IgA2 and discuss how subclass biology relates to selective IgA deficiency, IgA nephropathy, IgA vasculitis, celiac disease, linear IgA bullous dermatosis, dermatitis herpetiformis, IgA monoclonal gammopathies, and bacterial evasion of mucosal immunity. We also consider recent advances in genetics, biomarkers, and targeted therapies, including agents directed at the APRIL/BAFF pathway and at complement, and outline how an approach that takes subclasses and glycoforms into account may improve diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Basile et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: